A growing number of clinical trials have tried to confirm that EGFR-TKIs combined with angiogenesis inhibitors have superior anti-tumor action than the EGFR-TKIs monotherapy in advanced EGFR-mutant NSCLC, but these studies did not achieve completely consistent results. The gene discussed is EGFR; the disease is neoplasm.